Nicholas A. Marston

JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients.

Journal: Journal of clinical lipidology

Published: July 31, 2026

Evolocumab to Reduce Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis-Reply.

Journal: JAMA

Published: July 23, 2026

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 25, 2026

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 19, 2026

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 19, 2026

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Journal: Research square

Published: May 18, 2026

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Journal: Research square

Published: May 18, 2026

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Journal: Journal of clinical lipidology

Published: May 13, 2026

Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE.

Journal: Circulation

Published: May 11, 2026

Cardiovascular Regulatory Science: Accelerating the Path from Bench to Bedside.

Journal: American heart journal

Published: May 07, 2026

JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients.

JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients.

Evolocumab to Reduce Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis-Reply.

Evolocumab to Reduce Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis-Reply.

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE.

Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE.

Cardiovascular Regulatory Science: Accelerating the Path from Bench to Bedside.

Cardiovascular Regulatory Science: Accelerating the Path from Bench to Bedside.

The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies.

The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies.

Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. Reply.

Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. Reply.